Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

BACKGROUND: MET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these patients is undefined. Herein we report the cl...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Transl Med
Auteurs principaux: Wang, Wenxian, Wang, Hong, Lu, Peihua, Yu, Zongyang, Xu, Chunwei, Zhuang, Wu, Song, Zhengbo
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6385446/
https://ncbi.nlm.nih.gov/pubmed/30791921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-1803-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires